<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/29E726D1-A910-49D4-8EDF-CC9AB8A30630"><gtr:id>29E726D1-A910-49D4-8EDF-CC9AB8A30630</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Williams</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/31B1DA10-0186-4820-9445-F37DC43FCB16"><gtr:id>31B1DA10-0186-4820-9445-F37DC43FCB16</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Stocks</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BAB79EDD-7863-4741-AE51-143B974EB87A"><gtr:id>BAB79EDD-7863-4741-AE51-143B974EB87A</gtr:id><gtr:firstName>Miguel</gtr:firstName><gtr:surname>Camara</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FN501852%2F1"><gtr:id>E8E0C043-6606-481D-B52F-9CFD743AA915</gtr:id><gtr:title>SENBIOTAR: Sensiting Pseudomonas aeruginosa biofilms to antibiotics and reducing virulence through novel target inhibition</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/N501852/1</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The traditional approach to combating bacterial infections has been based on the use of antibiotics
which kill bacteria or inhibit their growth. There has also been a strong emphasis on the
identification of essential gene targets for drug intervention. A major problem with therapeutic
approaches targeting viability is that they induce strong selective pressures resulting in the rapid
emergence of antimicrobial resistance. An alternate approach is to inhibit virulence rather than
bacterial viability and this will be explored in the SENBIOTAR project. In the opportunistic human
pathogen Pseudomonas aeruginosa, virulence is co-ordinately controlled at the bacterial population
level through quorum sensing (QS), a global cell-to-cell communication system employing diffusible
signal molecules. P. aeruginosa strains with mutations in the Pseudomonas Quinolone Signal (PQS)
QS pathway are avirulent in experimental animal infections. The partners of this consortium will
exploit this information by optimising hit compounds and peptide nucleic acids (PNAs) they
identified previously which target PQS biosynthesis and/or PQS signal transduction. These hits have
been shown to not only render P. aeruginosa avirulent but also to sensitize biofilms to the action of
antibiotics. One of the limitations of using inhibitors of virulence is the fact that
immunocompromised patients may not be able to clear the targeted pathogen efficiently. However,
if the pathogen can, at the same time, be sensitised to antibiotics then there is great scope for dual
therapy with PQS inhibitors and antibiotics. SENBIOTAR will bring together world experts in QS,
medicinal chemistry, PNAs, drug delivery and preclinical studies to optimise the activity of the hit
compounds and PNAs (hit-to-lead optimization) with the intention of identifying lead compounds
which strongly inhibit QS, attenuate virulence and sensitise biofilms to conventional antibiotics at
sub-micromolar concentrations. This will be achieved by improving (a) their physicochemical
properties without the emergence of cytotoxicity, and (b) delivery to the site of infection. These
studies will be performed using a combination of in vitro virulence and biofilm bioassays alongside
experimental animal lung infection models. The lead compounds developed by SENBIOTAR will also
have significant potential for the treatment of wound, bloodstream and medical-device associated
infections caused by P. aeruginosa.</gtr:technicalSummary><gtr:fund><gtr:end>2018-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-05-31</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>358886</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>First Uganda National Conference on Antimicrobial Resistance</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>05228FBA-90BF-4013-A5CF-6E92DFFA4411</gtr:id><gtr:impact>Poster presentation of an MSc student who presented the research he carried out at Nottingham as part of the SENBIOTAR program. He represented to researchers in Uganda some of the highlights of this research program. The title of his poster was: Characterisation of inhibitors of the PqsR quorum sensing regulator in Pseudomonas aeruginosa.</gtr:impact><gtr:outcomeId>58a7338542b2b6.73524891</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oral presentation at the 5th UK Cystic Fibrosis Microbiology Consortium Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FF72ACD0-2AEA-4674-9DDB-8D44164C8F7F</gtr:id><gtr:impact>The activity was an oral presentation entitled: 'Targeting Pseudomonas aeruginosa virulence using novel inhibitors of the alkyl quinolone quorum sensing signalling pathway'. The idea was to inform academics, clinicians, postgraduates students and industry of the current work being carried out in the SENBIOTAR programme as an alternative approach to target Pseudomonas aeruginosa infections in the CF lung.</gtr:impact><gtr:outcomeId>58a72f334d81e7.39903249</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Postgraduate Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F6AFD792-A6DE-4B7A-9393-B17959ED0D25</gtr:id><gtr:impact>This was a training retreat for postgraduate students and the SENBIOTAR programme was introduced to them as part of a session entitled : 'Targeting virulence as an alternative approach to treat bacterial infections'. This was followed by a discussion with the students.</gtr:impact><gtr:outcomeId>58a72df1c18965.05275484</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Poster Presentation at the M4 Midland Molecular Microbiology Meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9215748A-DC8F-4B0C-B040-8BE6E4EB2171</gtr:id><gtr:impact>Symposium organise as a network activity for microbiology researchers in the Midlands including the Universities of Nottingham, Birmingham, Leicester and Warwick but there were also attendees from other Universities across the country.</gtr:impact><gtr:outcomeId>58a72cc5017dd9.48868014</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Early Discovery of New Antibiotics Workshop (Paris)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>31F61CBB-8C2A-4922-8870-EC1BB76E32A0</gtr:id><gtr:impact>The purpose of this workshop was to share ideas on antibiotic development between upstream and developers by bringing the PIs in project areas of antibiotic early discovery and those in clinical development in order to identify potential candidates and increase awareness of entry requirements. It also promote increased awareness at early stage of entry requirements about future clinical developments and showcased early work on screening and identification of new targets. The title of the presentation given by Miguel Camara was: SENBIOTAR: Sensitising Pseudomonas aeruginosa biofilms to antibiotics and reducing virulence through novel target inhibition.</gtr:impact><gtr:outcomeId>58a730d956abf6.16330415</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Third sector organisations</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>29F3AC3F-45B7-4335-9810-053638950307</gtr:id><gtr:title>Cystic Fibrosis Isolates of Pseudomonas aeruginosa Retain Iron-Regulated Antimicrobial Activity against Staphylococcus aureus through the Action of Multiple Alkylquinolones.</gtr:title><gtr:parentPublicationTitle>Frontiers in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e091967a41a90e0025351e258210ea0"><gtr:id>1e091967a41a90e0025351e258210ea0</gtr:id><gtr:otherNames>Nguyen AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1664-302X</gtr:issn><gtr:outcomeId>585d403dd5e772.21498257</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AF5BAA8-0C1A-44E7-A070-596665EC5B84</gtr:id><gtr:title>In Silico and in Vitro-Guided Identification of Inhibitors of Alkylquinolone-Dependent Quorum Sensing in Pseudomonas aeruginosa.</gtr:title><gtr:parentPublicationTitle>Molecules (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c80861a1167870af99bfb52116b2f3d"><gtr:id>4c80861a1167870af99bfb52116b2f3d</gtr:id><gtr:otherNames>Soukarieh F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1420-3049</gtr:issn><gtr:outcomeId>5a7ae5d2be0425.58261076</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/N501852/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>